Swiss National Bank Atea Pharmaceuticals, Inc. Transaction History

Swiss National Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$3.0 - $4.97 $57,600 - $95,424	-19,200 Reduced 10.61%	161,800 $542,000
Q4 2022 Feb 08, 2023	BUY	$4.35 - $6.17 $20,880 - $29,616	4,800 Added 2.72%	181,000 $870,000
Q2 2022 Aug 09, 2022	BUY	$5.33 - $8.18 $744,601 - $1.14 Million	139,700 Added 382.74%	176,200 $1.25 Million
Q2 2021 Aug 06, 2021	BUY	$19.22 - $59.08 $701,530 - $2.16 Million	36,500 New	36,500 $784,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $271M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.